Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 4.45 560 08:00:18
Bid Price Offer Price High Price Low Price Open Price
4.40 4.50 4.45 4.45 4.45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.17 -0.99 12
Last Trade Time Trade Type Trade Size Trade Price Currency
08:45:01 O 560 4.469 GBX

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Investors    Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date Time Title Posts
25/1/202311:42EVGEN PHARMA - 2022 BREAST CANCER TREATMENT SFX-011,231
02/11/202219:21EVGEN PHARMA - Well funded - A respected BOD - A rising Star214
10/10/202217:41Evgen Pharma PLC48
10/10/202210:33Evgen Guild thread151
10/10/202206:20Evgen Pharma: Undoubted Transformational Upside Potential2,433

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:45:024.4756025.03O
2023-01-26 11:57:224.491114.98O
2023-01-26 11:57:204.492229.97O
2023-01-26 11:56:474.40100,0004,402.00O
2023-01-26 10:20:034.5050,0002,250.00O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Top Posts
Posted at 12/1/2023 15:21 by lovewinshatelosses
It is certainly possible that some are cutting their losses to try their luck with some of the other names that are in a more positive trend. The trouble with that approach is that when news comes here (good news hopefully, and soon!) then it might be difficult to buy any sort of volume at a low price. But time will tell. If this one was on my watch list and I did not already have a position, not sure I would wait for 4p. Do not go all in, sure, but I would ladder in, personally. If you think the share price is going to drop far lower, then of course, wait and see. Either way, this one certainly tests one's patience :)
Posted at 11/1/2023 15:58 by clocktower
It is a pity that the board have not dug into their own pockets, as they cannot be in a closed period, as it is still a couple of months to end of year, and bearing in mind all the options they obtained it would have been a very good time to show they had a decent amount of skin in the game, particularly because the last time the share price was around it's current level, they were saying they wished they could buy. Well no sign of that yet, so I guess that is why there is little support at present.
Posted at 03/1/2023 21:34 by clocktower
Welcome back dave4545, it is not often that an opportunity the size of EVG presents itself and gets overlooked in favour of the likes of GENI that you were speaking about as the news they published today is not anywhere as good as the deals that have already been announced that provides funding for a long time ahead and huge prospects at the conclusion, let alone any more deals that may arise.

There is as you are no doubt aware a good possibility that someone could take advantage of the company’s low share price and snap it up for a song.

Posted at 14/12/2022 20:54 by lovewinshatelosses
What is the performance criteria? The strike price? I prefer it when this is clearly detailed - eg at 20p. Ideally on a scale, such as 15p/20p/25p tranches.
I think there needs to be plenty more in the near term pipeline to justify this award. Agree about the CBO though, On Target.
It does not change the investment case, but I do not see the market viewing this as excellent news. The CEO and CFO are salaried, not working on a share-only agreement.
I do not see this as acting as a positive catalyst for the share price tomorrow, but would be happy to be wrong. Not long to find out anyway.

Posted at 14/12/2022 19:42 by clocktower
I am happy that at the current share price the CFO’s options only amount to a decent littlebonus and bearing in mind that they vest in three years time and they have the terms clearly set out, I do not think it unreasonable.

As for Dr Jones total of 10 million plus you must look at the deals they have already pulled off. It is not as though the options were given before the deal. We know the current share price undervalues the company based on that last deal alone, so a fair reward in total of £500k at the current level is not unreasonable imo. Let’s hope the share price is £1 when he can sell them.
Good luck to him and all employees that are benefiting from this award.

Posted at 08/12/2022 09:48 by manual dexterity
A lot of companies that require cash have got them at significant discounts to prevailing share price. EVG requires no funds at all.

This is a double figure stock imo.

Posted at 21/10/2022 09:09 by lovewinshatelosses
I agree that once we get through the 8p sellers, 10p will likely be the next chief point of resistance. That last RNS has removed so much doubt and risk for at least the next 12 months IMO, that I am feeling more relaxed here than probably at any point since that 8p fund raise. Probably more actually, as I was disappointed at that time with what I felt was a low price, in that particular market cycle. Anyway, always fun to speculate while we wait for the share price to do whatever the share price is going to do and more importantly, further trial updates! GLA.
Posted at 12/10/2022 12:53 by lovewinshatelosses
The share price may well drift back somewhat in the weeks ahead without further news, but personally, I am confident in the direction of travel at this point in time. H1 2023 will come round in a flash, at which point I think the share price will be far higher than today. Or not, if things go wrong. Nothing is certain at this stage, but having been a holder here since 28p or so and now with an average below the last placing price in my core holding, I am more bullish than I have been before. But only my view. GLA.
Posted at 10/10/2022 07:02 by wapper
Irrespective of today's share price action this is big news and whilst EVG is not a short term bet there will be companies out there looking at how cheap this is now Vs how much potential gain there is within a relatively short term. EVG now in play.Only my opinion so please DYOR.
Posted at 13/6/2022 06:10 by manual dexterity
Evgen Pharma PLC
Collaboration with University of Michigan

RNS Number : 5593O
Evgen Pharma PLC
13 June 2022

Evgen Pharma plc

("Evgen" or the "Company")



Collaboration with University of Michigan to evaluate SFX-01 in models of colorectal cancer



Alderley Park, UK - 13 June 2022 : Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines for the treatment of cancer and other indications , announces a collaboration with Dr Grace Chen, of the University of Michigan, to investigate the potential anti-tumour effects of the Company's lead asset, SFX-01 in colorectal cancer.



SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Previous studies of the compound have shown in vivo and in vitro efficacy of the compound in a wide range of cancer cells including breast cancer, glioblastoma and certain blood cancers.



The collaboration with the University of Michigan seeks to evaluate the in vivo effects of SFX-01 in models of colorectal cancer. The effects and mechanism of action of SFX-01 on organoid growth, morphology, stemness and inflammatory markers will also be investigated, using normal and malignant patient-derived organoids and tumour tissue. Initial results are expected at the end of 2023.



Colorectal cancer is considered to be the third most common form of cancer worldwide, with between 1.5-2 million annual diagnoses, and second leading cause of cancer-related deaths. There has also been an alarming global rise in early-onset colorectal cancer occurring in individuals under 50 years of age. Treating colorectal cancers can be difficult and does not always lead to cure especially in advanced stages. Therefore, there is a strong need to develop chemoprevention strategies as well as better treatment options.



Dr Huw Jones, Evgen CEO, commented:

"This new project is our fifteenth pre-clinical collaboration to date. Colorectal cancer is a relatively common disease and a cancer type we have not explored extensively. The work of Dr. Chen's group will gain valuable insights into the effects of SFX-01 in models of colorectal cancer. Building on our existing promising data on the mode of action, efficacy and tolerability of our lead asset, we continue to develop our core products to address the widest possible range of indications."



Dr Grace Chen, of the University of Michigan, lead investigator, commented:

"We have seen the encouraging data of SFX-01 in various indications and want to understand more about the potential of Evgen's sulforaphane-synthetising technology in colorectal cancer to help develop prevention strategies especially in high-risk patients and improved treatment options for patients with advanced colorectal cancer."



Evgen's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. Sulforaphanes have shown potential benefits in oncology by reducing inflammation and blocking DNA mutation of cancer.



-Ends-

Evgen Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230127 09:22:01